Ann: Quarterly Report - December 2018, page-105

Yep, I said a while ago that a deal hasn't been done because the offers being made for SDV are duds. That's why GXY keeps saying it won't do a deal unless the offer "recognize the fundamental underlying value". Read between the lines. Most on here have this misjudged belief that companies are falling over themselves to partner with SDV. Companies are only interested in partnering with SDV if GXY lowers its expectations on what a mutual deal looks like. With the price of spodumene "notably" down on 2018 and GXY's tiny market cap, GXY doesn't have much bargaining power, IMO.